The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury

[1]  P. Perel,et al.  Beta‐2 Receptor Antagonists for Traumatic Brain Injury: A Systematic Review of Controlled Trials in Animal Models , 2009, CNS neuroscience & therapeutics.

[2]  D. Cook,et al.  Serious adverse events in academic critical care research , 2008, Canadian Medical Association Journal.

[3]  K. Ker,et al.  Beta‐2 receptor antagonists for acute traumatic brain injury , 2007 .

[4]  A. Marmarou,et al.  A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. , 2005, Journal of neurotrauma.

[5]  G. Bernard,et al.  Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment* , 2005, Critical care medicine.

[6]  B. Palmier,et al.  LF 16‐0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia , 2003, British journal of pharmacology.

[7]  N. Plesnila,et al.  Effects of LF 16-0687 Ms, a bradykinin B2 receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia , 2002, Brain Research.

[8]  A. Artru,et al.  LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. , 2002, Journal of neurotrauma.

[9]  T. Yamamoto,et al.  Contribution of edema and cerebral blood volume to traumatic brain swelling in head-injured patients. , 2000, Journal of neurosurgery.

[10]  M. Wahl,et al.  Brain edema: pathogenesis and therapy. , 1997, Kidney international. Supplement.

[11]  A. Unterberg,et al.  Vasomotor and permeability effects of bradykinin in the cerebral microcirculation. , 1996, Immunopharmacology.

[12]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[13]  S. Zanotti-Cavazzoni.  Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment , 2007 .

[14]  Robert Tibshirani,et al.  An Introduction to the Bootstrap CHAPMAN & HALL/CRC , 1993 .